Moderna (MRNA) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

MRNA Stock Forecast

Moderna stock forecast is as follows: an average price target of $140.57 (represents a 280.54% upside from MRNA’s last price of $36.94) and a rating consensus of 'Hold', based on 25 wall street analysts offering a 1-year stock forecast.

MRNA Price Target

The average price target for Moderna (MRNA) is $140.57 based on 1-year price targets from 25 Wall Street analysts in the past 3 months, with a price target range of $304.00 to $55.00. This represents a potential 280.54% upside from MRNA's last price of $36.94.

MRNA Analyst Ratings

Hold

According to 25 Wall Street analysts, Moderna's rating consensus is 'Hold'. The analyst rating breakdown for MRNA stock is 0 'Strong Buy' (0.00%), 9 'Buy' (36.00%), 15 'Hold' (60.00%), 1 'Sell' (4.00%), and 0 'Strong Sell' (0.00%).

Moderna Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 18, 2024	Edward Tenthoff	Piper Sandler	$69.00	$37.27	85.13%	86.79%
Nov 18, 2024	Yifeng Liu	HSBC	$58.00	$84.93	-31.71%	57.01%
Oct 17, 2024	Courtney Breen	Bernstein	$55.00	$57.46	-4.28%	48.89%
Oct 14, 2024	Michael Yee	Jefferies	$55.00	$57.73	-4.73%	48.89%
Sep 13, 2024	Edward Tenthoff	Piper Sandler	$115.00	$69.68	65.04%	211.32%
Sep 13, 2024	Luca Issi	RBC Capital	$75.00	$69.68	7.63%	103.03%
Sep 13, 2024	Leah Rush Cann	Loop Capital Markets	$238.00	$69.68	241.56%	544.29%
Sep 12, 2024	Michael Yee	Jefferies	$65.00	$69.68	-6.72%	75.96%
Sep 12, 2024	Cory Kasimov	Evercore ISI	$105.00	$67.68	55.14%	184.24%
Sep 12, 2024	Matthew Harrison	Morgan Stanley	$94.00	$67.51	39.24%	154.47%

Row per page

Go to

The latest Moderna stock forecast, released on Nov 18, 2024 by Edward Tenthoff from Piper Sandler, set a price target of $69.00, which represents a 85.13% increase from the stock price at the time of the forecast ($37.27), and a 86.79% increase from MRNA last price ($36.94).

Moderna Price Target by Period

	1M	3M	12M
# Anlaysts	2	13	34
Avg Price Target	$63.50	$103.92	$124.15
Last Closing Price	$36.94	$36.94	$36.94
Upside/Downside	71.90%	181.32%	236.09%

In the current month, the average price target of Moderna stock is $63.50, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 71.90% increase as opposed to Moderna's last price of $36.94. This month's average price target is down -38.90% compared to last quarter, and down -48.85% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 24, 2024	Piper Sandler	Overweight	Overweight	Hold
Oct 21, 2024	Cowen & Co.	Hold	Hold	Hold
Oct 17, 2024	Bernstein	-	Market Perform	Initialise
Oct 15, 2024	Sandler O'Neill	Sector Perform	Sector Perform	Hold
Oct 15, 2024	Sandler O'Neil	Underperform	Underperform	Hold
Oct 14, 2024	Jefferies	Hold	Hold	Hold
Sep 13, 2024	Sandler O'Neill	Sector Perform	Sector Perform	Hold
Sep 13, 2024	Piper Sandler	Overweight	Overweight	Hold
Sep 13, 2024	Oppenheimer	Outperform	Perform	Downgrade
Sep 13, 2024	RBC Capital	Sector Perform	Sector Perform	Hold

Row per page

Go to

Moderna's last stock rating was published by Piper Sandler on Oct 24, 2024. The company gave MRNA a "Overweight" rating, the same as its previous rate.

Moderna Financial Forecast

Moderna Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	$1.83B	$344.00M	$1.86B	$5.08B	$3.22B	$4.57B	$5.94B	$7.21B	$4.97B	$4.35B	$1.94B	$570.75M	$157.91M	$66.35M	$8.39M	$14.05M	$17.05M
Avg Forecast	$1.51B	$1.27B	$114.70M	$160.30M	$1.11B	$1.34B	$174.39M	$216.06M	$1.08B	$1.25B	$128.41M	$93.26M	$2.51B	$1.38B	$307.67M	$1.18B	$5.02B	$3.53B	$4.10B	$4.20B	$6.80B	$6.08B	$4.21B	$2.05B	$279.41M	$80.60M	$27.51M	$17.60M	$17.37M	$17.64M
High Forecast	$2.24B	$1.89B	$170.24M	$237.92M	$1.65B	$1.99B	$258.84M	$260.06M	$1.48B	$1.27B	$128.41M	$93.26M	$2.91B	$1.92B	$456.64M	$1.75B	$7.45B	$3.53B	$4.10B	$4.20B	$6.80B	$6.08B	$4.21B	$2.05B	$279.41M	$80.60M	$27.51M	$17.60M	$17.37M	$17.64M
Low Forecast	$1.18B	$995.06M	$89.77M	$125.46M	$870.71M	$1.05B	$136.49M	$159.82M	$912.50M	$1.23B	$128.41M	$93.26M	$2.21B	$509.40M	$240.80M	$922.04M	$3.93B	$3.53B	$4.10B	$4.20B	$6.80B	$6.08B	$4.21B	$2.05B	$279.41M	$80.60M	$27.51M	$17.60M	$17.37M	$17.64M
# Analysts	4	4	4	4	3	3	3	5	10	9	9	9	10	13	6	6	5	5	5	11	12	11	10	9	9	8	7	6	5	5
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.32%	1.12%	1.58%	1.01%	0.91%	1.11%	1.41%	1.06%	0.82%	1.03%	0.94%	2.04%	1.96%	2.41%	0.48%	0.81%	0.97%

Moderna's average Quarter revenue forecast for Dec 23 based on 10 analysts is $2.51B, with a low forecast of $2.21B, and a high forecast of $2.91B. MRNA's average Quarter revenue forecast represents a 37.14% increase compared to the company's last Quarter revenue of $1.83B (Sep 23).

Moderna EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	4	4	4	4	3	3	3	5	10	9	9	9	10	13	6	6	5	5	5	11	12	11	10	9	9	8	7	6	5	5
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	$-2.01B	$-1.87B	$-288.00M	$1.58B	$1.34B	$2.45B	$4.32B	$5.49B	$3.63B	$3.14B	$1.28B	$-259.80M	$-221.44M	$-107.09M	$-115.05M	$-112.35M	$-114.56M
Avg Forecast	$-365.05M	$-307.57M	$-27.75M	$-38.78M	$-269.13M	$-324.74M	$-42.19M	$-52.27M	$-262.35M	$-302.42M	$-31.06M	$-22.56M	$-607.47M	$-334.93M	$-74.43M	$-285.00M	$-1.21B	$-859.55M	$-998.59M	$3.69B	$-1.66B	$-1.48B	$-1.03B	$1.04B	$-68.10M	$-19.65M	$-6.71M	$-115.05M	$-4.23M	$-4.30M
High Forecast	$-285.71M	$-240.72M	$-21.72M	$-30.35M	$-210.64M	$-254.16M	$-33.02M	$-38.66M	$-220.75M	$-296.39M	$-31.06M	$-22.56M	$-534.58M	$-123.23M	$-58.25M	$-223.06M	$-949.97M	$-859.55M	$-998.59M	$4.43B	$-1.66B	$-1.48B	$-1.03B	$1.24B	$-68.10M	$-19.65M	$-6.71M	$-92.04M	$-4.23M	$-4.30M
Low Forecast	$-541.81M	$-456.50M	$-41.18M	$-57.56M	$-399.45M	$-481.98M	$-62.62M	$-62.91M	$-356.89M	$-308.44M	$-31.06M	$-22.56M	$-704.67M	$-465.15M	$-110.47M	$-423.00M	$-1.80B	$-859.55M	$-998.59M	$2.95B	$-1.66B	$-1.48B	$-1.03B	$829.90M	$-68.10M	$-19.65M	$-6.71M	$-138.06M	$-4.23M	$-4.30M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	6.01%	25.08%	1.01%	-1.30%	-1.56%	-2.45%	1.17%	-3.32%	-2.45%	-3.06%	1.23%	3.81%	11.27%	15.97%	1.00%	26.53%	26.64%

6 analysts predict MRNA's average Quarter EBITDA for Mar 23 to be $-285.00M, with a high of $-223.06M and a low of $-423.00M. This is -118.04% lower than Moderna's previous annual EBITDA (Dec 22) of $1.58B.

Moderna Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	4	4	4	4	3	3	3	5	10	9	9	9	10	13	6	6	5	5	5	11	12	11	10	9	9	8	7	6	5	5
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	$-3.63B	$-1.38B	$79.00M	$1.47B	$1.04B	$2.20B	$3.66B	$4.87B	$3.33B	$2.78B	$1.22B	$-272.49M	$-233.64M	$-116.71M	$-124.23M	$-123.12M	$-123.19M
Avg Forecast	$-330.93M	$-453.78M	$-1.15B	$-1.07B	$-660.35M	$-533.85M	$-1.23B	$-1.21B	$-1.06B	$-720.00M	$-1.34B	$3.79B	$-393.73M	$-770.99M	$-1.57B	$3.44B	$4.60B	$1.27B	$1.76B	$3.13B	$3.83B	$3.45B	$2.29B	$991.10M	$-131.52M	$-145.22M	$-135.45M	$-124.23M	$-161.28M	$-167.86M
High Forecast	$-237.42M	$-325.56M	$-823.54M	$-769.24M	$-473.77M	$-383.01M	$-883.71M	$-1.11B	$-677.44M	$-516.56M	$-958.47M	$4.55B	$1.62B	$-267.05M	$-1.13B	$4.13B	$5.52B	$1.27B	$1.76B	$3.76B	$3.83B	$3.45B	$2.29B	$1.19B	$-131.52M	$-145.22M	$-135.45M	$-99.38M	$-161.28M	$-167.86M
Low Forecast	$-539.24M	$-739.43M	$-1.87B	$-1.75B	$-1.08B	$-869.89M	$-2.01B	$-1.30B	$-1.57B	$-1.17B	$-2.18B	$3.03B	$-1.37B	$-1.49B	$-2.56B	$2.75B	$3.68B	$1.27B	$1.76B	$2.50B	$3.83B	$3.45B	$2.29B	$792.88M	$-131.52M	$-145.22M	$-135.45M	$-149.08M	$-161.28M	$-167.86M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	4.71%	0.88%	0.02%	0.32%	0.82%	1.25%	1.17%	1.27%	0.97%	1.22%	1.23%	2.07%	1.61%	0.86%	1.00%	0.76%	0.73%

Moderna's average Quarter net income forecast for Jun 23 is $-1.57B, with a range of $-2.56B to $-1.13B. MRNA's average Quarter net income forecast represents a -2087.27% decrease compared to the company's last Quarter net income of $79.00M (Mar 23).

Moderna SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	4	4	4	4	3	3	3	5	10	9	9	9	10	13	6	6	5	5	5	11	12	11	10	9	9	8	7	6	5	5
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	$442.00M	$332.00M	$305.00M	$375.00M	$278.00M	$211.00M	$268.00M	$201.00M	$168.00M	$121.00M	$77.00M	$78.99M	$48.54M	$36.62M	$24.11M	$25.63M	$28.19M
Avg Forecast	$991.37M	$835.27M	$75.35M	$105.31M	$730.89M	$881.90M	$114.57M	$141.94M	$712.45M	$821.27M	$84.36M	$61.27M	$1.65B	$909.56M	$202.13M	$252.33M	$190.06M	$2.32B	$2.69B	$229.39M	$4.47B	$4.00B	$2.77B	$62.50M	$183.74M	$53.00M	$18.09M	$11.57M	$11.42M	$11.60M
High Forecast	$1.47B	$1.24B	$111.84M	$156.31M	$1.08B	$1.31B	$170.05M	$170.85M	$969.19M	$837.63M	$84.36M	$61.27M	$1.91B	$1.26B	$300.00M	$302.80M	$228.07M	$2.32B	$2.69B	$275.27M	$4.47B	$4.00B	$2.77B	$75.00M	$183.74M	$53.00M	$18.09M	$11.57M	$11.42M	$11.60M
Low Forecast	$775.89M	$653.73M	$58.98M	$82.42M	$572.03M	$690.22M	$89.67M	$105.00M	$599.49M	$804.90M	$84.36M	$61.27M	$1.45B	$334.66M	$158.20M	$201.87M	$152.05M	$2.32B	$2.69B	$183.52M	$4.47B	$4.00B	$2.77B	$50.00M	$183.74M	$53.00M	$18.09M	$11.57M	$11.42M	$11.60M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.49%	1.64%	1.21%	1.97%	0.12%	0.08%	1.17%	0.04%	0.04%	0.04%	1.23%	0.43%	0.92%	2.02%	2.08%	2.24%	2.43%

Moderna's average Quarter SG&A projection for Dec 23 is $1.65B, based on 10 Wall Street analysts, with a range of $1.45B to $1.91B. The forecast indicates a 273.24% rise compared to MRNA last annual SG&A of $442.00M (Sep 23).

Moderna EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	4	4	4	4	3	3	3	5	10	9	9	9	10	13	6	6	5	5	5	11	12	11	10	9	9	8	7	6	5	5
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	$-9.53	$-3.62	$0.20	$3.81	$2.67	$5.55	$9.09	$12.02	$8.27	$6.93	$3.05	$-0.69	$-0.59	$-0.31	$-0.35	$-0.37	$-0.37
Avg Forecast	$-0.83	$-1.14	$-2.88	$-2.69	$-1.66	$-1.34	$-3.09	$-3.02	$-2.67	$-1.80	$-3.35	$-3.56	$-0.99	$-1.93	$-3.93	$-1.75	$4.60	$3.30	$4.58	$5.37	$9.96	$8.97	$5.96	$2.43	$-0.34	$-0.38	$-0.35	$-0.35	$-0.42	$-0.44
High Forecast	$-0.60	$-0.82	$-2.06	$-1.93	$-1.19	$-0.96	$-2.21	$-2.79	$-1.70	$-1.29	$-2.40	$-2.55	$4.07	$-0.67	$-2.82	$-1.25	$7.50	$3.30	$4.58	$5.37	$9.96	$8.97	$5.96	$2.43	$-0.34	$-0.38	$-0.35	$-0.35	$-0.42	$-0.44
Low Forecast	$-1.35	$-1.85	$-4.69	$-4.38	$-2.70	$-2.18	$-5.03	$-3.25	$-3.93	$-2.94	$-5.46	$-5.80	$-3.44	$-3.72	$-6.41	$-2.85	$3.30	$3.30	$4.58	$5.37	$9.96	$8.97	$5.96	$2.43	$-0.34	$-0.38	$-0.35	$-0.35	$-0.42	$-0.44
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	4.93%	0.92%	-0.11%	0.83%	0.81%	1.21%	1.69%	1.21%	0.92%	1.16%	1.25%	2.01%	1.56%	0.88%	0.99%	0.88%	0.85%

According to 6 Wall Street analysts, Moderna's projected average Quarter EPS for Jun 23 is $-3.93, with a low estimate of $-6.41 and a high estimate of $-2.82. This represents a -2067.34% decrease compared to MRNA previous annual EPS of $0.20 (Mar 23).

Moderna Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
HEPA	Hepion Pharmaceuticals	$0.69	$70.00	10044.93%	Buy
ELEV	Elevation Oncology	$0.58	$9.00	1451.72%	Buy
CVAC	CureVac	$2.49	$29.00	1064.66%	Buy
NTLA	Intellia Therapeutics	$13.12	$115.90	783.38%	Buy
NVAX	Novavax	$8.06	$50.80	530.27%	Buy
EDIT	Editas Medicine	$2.41	$12.85	433.20%	Buy
MRNA	Moderna	$36.94	$140.57	280.54%	Hold
BEAM	Beam Therapeutics	$24.49	$58.50	138.87%	Buy
DNA	Ginkgo Bioworks	$6.36	$7.34	15.41%	Buy
KRYS	Krystal Biotech	$178.10	$191.00	7.24%	Buy
VRTX	Vertex Pharmaceuticals	$451.23	$403.92	-10.48%	Buy

MRNA Forecast FAQ

Is Moderna a good buy?

No, according to 25 Wall Street analysts, Moderna (MRNA) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 9 'Buy' recommendations, accounting for 36.00% of MRNA's total ratings.

What is MRNA's price target?

Moderna (MRNA) average price target is $140.57 with a range of $55 to $304, implying a 280.54% from its last price of $36.94. The data is based on 25 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Moderna stock go up soon?

According to Wall Street analysts' prediction for MRNA stock, the company can go up by 280.54% (from the last price of $36.94 to the average price target of $140.57), up by 722.96% based on the highest stock price target, and up by 48.89% based on the lowest stock price target.

Can Moderna stock reach $60?

MRNA's average twelve months analyst stock price target of $140.57 supports the claim that Moderna can reach $60 in the near future.

What is Moderna's current price target trend?

2 Wall Street analysts forecast a $63.5 price target for Moderna (MRNA) this month, up 71.90% from its last price of $36.94. Compared to the last 3 and 12 months, the average price target increased by 181.32% and increased by 236.09%, respectively.

What are Moderna's analysts' financial forecasts?

Moderna's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $2.85B (high $4.16B, low $2.22B), average EBITDA is $-688M (high $-536M, low $-1.007B), average net income is $-3.631B (high $-2.855B, low $-5.249B), average SG&A $1.87B (high $2.73B, low $1.46B), and average EPS is $-9.1 (high $-7.155, low $-13.155). MRNA's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $3.06B (high $4.53B, low $2.39B), average EBITDA is $-739M (high $-578M, low $-1.097B), average net income is $-3.005B (high $-2.156B, low $-4.896B), average SG&A $2.01B (high $2.98B, low $1.57B), and average EPS is $-7.531 (high $-5.403, low $-12.271).

Did the MRNA's actual financial results beat the analysts' financial forecasts?

Based on Moderna's last annual report (Dec 2022), the company's revenue was $19.26B, beating the average analysts forecast of $16.84B by 14.36%. Apple's EBITDA was $9.77B, beating the average prediction of $620.66M by 1473.81%. The company's net income was $8.36B, missing the average estimation of $10.76B by -22.28%. Apple's SG&A was $1.13B, missing the average forecast of $5.43B by -79.16%. Lastly, the company's EPS was $21.26, beating the average prediction of $17.86 by 19.07%. In terms of the last quarterly report (Sep 2023), Moderna's revenue was $1.83B, beating the average analysts' forecast of $1.38B by 32.25%. The company's EBITDA was $-2.012B, beating the average prediction of $-335M by 500.73%. Moderna's net income was $-3.63B, beating the average estimation of $-771M by 370.82%. The company's SG&A was $442M, missing the average forecast of $909.56M by -51.41%. Lastly, the company's EPS was $-9.53, beating the average prediction of $-1.932 by 393.19%